Avid Bioservices Inc (CDMO)

[entdoc]

EastCoastGuy, your narrative about DNDN and its prostate drug, Provenge, and DNDN similarities to PPHM, mentioned stock price, financing, etc. but did not deal with a comparison in product efficacy. To all you guys still wearing a prostate, a recent article by Seal, et.al., included DNDN's Provenge (sipuleucel-T) in the mix, and concluded, "The results of this review demonstrate that the therapeutic landscape of MPC (metastatic prostate CA) has changed dramatically and many therapies in MPC now show OS improvements of about 4 months in the postdocetaxel setting. Study: Of 77 studies identified, 26 (34%) evaluated survival as an end point; 14 (18%) assessed PROs/tolerability. In chemotherapy-naive patients (no/minimal symptoms), median overall survival (OS) was 26 months for sipuleucel-T. In relapsed patients, the survival benefit of cabazitaxel/abiraterone was 15 months and that of enzalutamide was 18 months. Denosumab prolonged time to first on-study skeletal-related event (20.7 months denosumab, 17.1 months zoledronic acid; P = 0.0002, noninferiority; P = 0.008, superiority). Similar benefit was documented with radium-223, a new bone-targeted a-particle-emitting radiopharmaceutical. Radium-223 also significantly improved the OS (two-sided P = 0.00185). Specific to PROs, they were incorporated primarily as secondary end points, and improvements in pain response (most commonly evaluated) were variable among the agents. Last, the therapies were associated with unique toxicities requiring careful consideration.Value Health.
2013 Jul-Aug;16(5):872-90. doi: 10.1016/j.jval.2013.03.1628. Epub 2013 Jul 10.

Efficacy, patient-reported outcomes (PROs), and tolerability of the changing therapeutic landscape in patients with metastatic prostate cancer (MPC): a systematic literature review.
Seal BS, Asche CV, Puto K, Allen PD.2013 Jul-Aug;16(5):872-90. doi: 10.1016/j.jval.2013.03.1628. Epub 2013 Jul 10.